No CEO feels company is ever fully valued: ex-HGS chief
This article was originally published in Scrip
Executive Summary
Months after the acrimonious takeover of Human Genome Sciences (HGS) by GlaxoSmithKline, the US biotech's former CEO said that he was 'pleased' that the deal had happened but tactfully maintained that HGS was probably worth more while also underscoring the potential of Benlysta (belimumab) globally.